DOCT — Beyond Medical Technologies Income Statement
0.000.00%
Last trade - 00:00
- CA$0.40m
- CA$0.33m
2018 December 31st | 2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.209 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | — | — | 0.025 | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.08 | 5.78 | 6.52 | 1.47 | 0.839 |
Operating Profit | -3.08 | -5.78 | -6.32 | -1.47 | -0.839 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.21 | -5.37 | -6.52 | -1.87 | -0.835 |
Net Income After Taxes | -3.21 | -5.37 | -6.52 | -1.87 | -0.835 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -3.21 | -5.37 | -6.52 | -2.91 | -1.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.21 | -5.37 | -6.52 | -2.91 | -1.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.838 | -0.606 | -0.479 | -0.248 | -0.106 |